Parnassus Investments, an investment management company, released the “Parnassus Mid Cap Fund” third-quarter 2025 investor ...

Insulet Corporation (NASDAQ:PODD) is one of the Best Fundamental Stocks to Buy According to Analysts. On January 9, Bernstein ...

PODD gains momentum as Omnipod 5 adoption accelerates, margins scale, and earnings estimates rise despite macro and concentration risks.

Insulet stock (NASDAQ: PODD) currently trades around $200 per share, about 35% lower than the levels of over $300 seen in early November 2021. In comparison, its peer – DexCom stock – is down 55% over ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks ...

Insulet Corporation’s PODD rapid commercial expansion and increasing market access capabilities for its Omnipod platform are poised to help it grow in the upcoming quarters. The rising adoption of ...

Fintel reports that on January 12, 2026, Barclays downgraded their outlook for Insulet (NasdaqGS:PODD) from Equal-Weight to ...

(Photo by Kirk Mckoy/Los Angeles Times via Getty Images) When it comes to surgical innovation, Intuitive Surgical (NASDAQ: ISRG) often dominates investor attention. But Insulet Corporation (NASDAQ: ...

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a ...

Insulet Corporation (NASDAQ:PODD) reported Q3 sales of $432.7 million, up 27.0%, or 25.1% in constant currency, beating the consensus of $414.383 million. Total Omnipod revenue of $422 million marked ...